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PEPTIDE-DRUG CONJUGATE FOR HER2-TARGETED DRUG DELIVERY 
 
 
Abstract 
 
By Yan Wang 
University of the Pacific 
2018 
Recent strategies for anticancer drug design have been focused on utilizing 
antibody as a drug or targeted moiety for targeted drug delivery. Antibody−drug 
conjugates (ADCs) have become a promising new class of targeted therapeutic agents 
for treatment of cancer. ADCs are designed to preferentially direct a cytotoxic drug to 
a cell-surface antigen recognized by an antibody. However, there are some challenges 
in developing ADCs, such as limited solid tumor penetration, high manufacturing 
costs and antibody-drug stoichiometry. Smaller molecules such as peptides have been 
shown to specifically bind to cancer related targets. These peptides can be used to 
form peptide-drug conjugates (PDCs) to overcome above-mentioned drawbacks 
presented by ADCs.   
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In this study, it was hypothesized that novel synthesized PDCs can be a strategy 
for breast cancer therapy. HER2 specific binding peptides, MARAKE and MARSGL, 
were modified by addition of a cysteine at C-terminus. The modified peptides were 
coupled with monomethylauristatin E (MMAE) by using maleimidocaproyl (MC) as a 
non-cleavable linker to form peptide-drug conjugates (YW1, YW2) and 
maleimidocaproyl-valine-citrulline (MC-VC) as a cleavable linker to form 
peptide-drug conjugates (YW3 and YW4). The peptides, peptide-drug conjugates and 
MC-MMAE, MC-VC-MMAE were characterized using ESI-MS and purified by 
using high-performance liquid chromatography (HPLC). Cellular uptake study was 
performed to determine binding specificity and internalization of two HER2 specific 
peptides and cysteine-modified peptides (MARAKEC, MARSGLC). In vitro cell 
viability assay was conducted to assess the cytotoxicity and determine the targeting 
specificity as well as the potency of the peptide-drug conjugates.  
The purity of each compound was greater than 90%. Internalization of both 
HER2 specific binding peptides and cysteine-modified peptides were significantly 
higher than random peptides in HER2 over-expressed cell lines, MDA-MB361 and 
ZR75, while negligible uptake in HER2 negative cell line, HEK293. MC linked PDCs 
showed similar cytotoxicity as peptide in all cell lines; while MC-VC linked PDCs 
have higher cytotoxicity than MMAE in HER2 positive cell line and significant lower 
cytotoxicity than MMAE in normal cell line HEK293. However, PDCs with MC link 
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do not show significant difference in cytotoxicity compared to the peptide in all cell 
lines. 
In conclusion, specificity of HER2 binding for both peptides was preserved after 
modification with cysteine.  The derivation of MMAE to link drug and peptide 
played a crucial role in the anticancer activity.  Peptide-MMAE conjugates with 
cleavable linker showed a promising targeting capability for delivery of MMAE to 
HER2 overexpressed cancer cells.
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CHAPTER 1: INTRODUCTION 
 
1.1. Cancer Therapy and Anti-cancer Drugs 
According to the World Health Organization (WHO) statistics, 3/5 of death in the 
world is attributable to cancer, diabetes, cardiovascular disease, and chronic 
respiratory system disease; of these four categories of diseases, cancer is one of the 
leading causes of death.  
Several approaches to cancer treatment have been used for cancer therapy, 
including surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, 
hormone therapy, stem cell transplant, and precision medicine. Among them, 
chemotherapy, hormone therapy, immunotherapy, and target therapy use anticancer 
drug. Anti-cancer drugs can also be classified into four types based on the mechanism 
and site of action, including the direct effects on DNA, drugs that disrupt its structure 
and function; interference with DNA synthesis; antimitotic drugs; and drug 
mechanism based on tumor biology. 
 DNA-damaging Drugs 1.1.1.
 Alkylating Agents 1.1.1.1.
Alkylating agents are a class of cytotoxic drugs that possess highly reactive 
chemical properties. These molecules contain one to two alkyls groups, which can be 
transformed into electron-deficient intermediate. These intermediate products 
19 
 
 
  
covalently combine with DNA electrons in an alkylation reaction, resulting in the loss 
of function of DNA in cell metabolism; thereby the cell composition is affected, 
resulting in variation of cell division and, ultimately, cell death. 
 Platinum Compounds 1.1.1.2.
Cisplatin is a nonspecific drug that when enters the cell cycle after internalization 
into tumor cells and hydrolyzes the target molecule, such as cisplatin, carboplatin, and 
oxaliplatin. This hydrolyzed complex interacts with DNA and forms a chelate ring 
that results in the partial denaturation and loss of replicative capacity of the DNA [1]. 
Cisplatin also reacts with cellular proteins and RNA and forms inactive molecules 
like glutathione and cysteine. Because of the rapid speed of proliferation and 
synthesis in cancers, platinum compounds have a higher cytotoxic effect on cancer 
cells than normal cells. 
 Bleomycin 1.1.1.3.
Bleomycin is a glycopeptide antibiotic produced by Streptomyces verticillus that 
causes DNA strand break by binding to DNA and inhibiting thymidine entry into 
DNA. The breaking of DNA strands leads to the inhibition of DNA synthesis and cell 
proliferation [2]. 
 Drug Interference with DNA Synthesis 1.1.2.
Drug interference in DNA synthesis is also called as anti-metabolites, as it occurs 
by the inhibition of DNA synthesis of folic acid, purine, pyridine, and pyridine 
metabolism, thereby inhibiting the survival and replication of tumor cells, leading to 
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tumor cell death. This kind of drug can be classified further into folic acid 
antagonists.  
 Antimitotic Drugs 1.1.3.
Mitosis is a vulnerable stage in the survival of carcinoma cells, and therefore it 
can be used to design drugs for anticancer intervention. Microtubule and associated 
proteins play a vital role in the process of mitosis; microtubule-targeted drugs may 
interfere with microtubule dynamics to activate the spindle assembly checkpoint 
(SAC), induce mitotic arrest, and cause cell death ultimately [3]. There are two types 
of mitosis drugs according to the mechanism involved, namely, 
microtubule-destabilizing agents and microtubule-stabilizing agents [4]. Destabilizing 
agents inhibit the polymerization of microtubules in high concentration, and most of 
them bind to the taxoid-binding domain or vinca domain [5].  
Microtubule-stabilizing agents enhance microtubule polymerization, stabilize 
microtubules, and prevent Ca2+ and subsequent disassembly [6].  
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Figure 1.1 Four categories of anticancer drugs 
1.2. Drug Delivery in Cancer 
Anti-cancer drugs kill rapidly proliferating cells, which is not limited to cancer 
cells only, resulting in side-effects such as hair loss, reduced blood cells, and stomach 
irritation. However, discontinuation of drug therapy may result in cancer recurrence, 
resulting in rapid proliferation of cells again [7]. In order to completely eradicate 
cancer cells and reduce undesired side-effects, the strategy to deliver drugs to a target 
tumor site has been proposed.  
 Passive Target Delivery System 1.2.1.
Passive targeting delivery system is designed to deliver the drug to the systemic 
circulation by using the body's natural response to specific physicochemical 
Anti cancer drugs Cytotoxic drugs 
Drugs that 
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characteristics. Rapid growing tumors generate new vessels or reroute the existing 
vessels in order to adequate supply of nutrients and oxygen, [8] which causes 
imbalance of angiogenic regulator, resulting in tumor vessel disorganization and 
expansion, with a gap junction between the endothelial cells, thereby causing 
enhanced permeability of the tumor vessel [9]. Because of the impaired clearance 
system in the tumor tissues, macromolecules and lipids stay in the tumor interstitial 
space for a long time [10]. This phenomenon is termed as tumor-selective enhanced 
permeation and retention (EPR) effect of nanoparticles. The EPR effect has been 
widely used to design passive-target delivery system because it meets the four 
requirements of effective target drug delivery system, that is, retain, evade, target, and 
release [11].  
For obtaining abundant supply of nutrition and oxygen for the new vessels 
generated, the rapidly growing tumor cells use glycolysis to obtain extra energy to 
maintain their rapid metabolic rate, resulting in an acidic tumor microenvironment 
[12]. Several approaches such as the use of pH-sensitive liposome have been used to 
design pH-sensitive drug carriers that have stable physiologic pH (7.4), but which 
degrade and release in the target tumor tissue with lower pH value [13].  
pH-sensitive nanoparticles are devised to combine EPR effect and pH-trigger 
release. The loaded drug accumulated in tumor via the EPR effect while remained 
stable during blood circulation and released the encapsulated medications into acidic 
environment provided by the solid tumor [14]. 
23 
 
 
  
 Active Target Delivery System 1.2.2.
Active target delivery is designed to overcome the limited specificity of the 
passive delivery system. This delivery system is based on the ligand–receptor 
interaction that happens between delivery system and target when the delivery system 
meets the target cells where there is efficient interaction between the ligands and 
receptors [7]. For example, epidermal growth factor receptors (EGFR) are proteins 
overexpressed on the surface of cells that can be used for targeting delivery via 
specific ligand receptor interaction mechanism. To achieve efficient ligand–receptor 
interaction, several factors should be considered: the extent and homogeneity of target 
cell antigen or receptor expression, the availability of cell surface receptor on the cell 
surface, the rate of drug release, and internalization.  
1.3. Therapeutic Monoclonal Antibody 
Monoclonal antibody is developed and designed to target overexpressed antigen 
on or near the surface of malignant cells [15]. Therapeutic monoclonal antibody can 
be used as a treatment option in several diseases such as oncology, inflammation, 
cardiovascular diseases, and infectious diseases. Antibody exerts two important 
functions, including binding and modulating antigen and binding complement and 
immune-effector cells [16]. Tumor-targeting monoclonal antibody can be grouped 
into six classes based on the functional consideration: (1) mAbs that inhibits the 
intrinsic proliferation signal transduction pathway; (2) mAbs that activate the cell 
surface cytotoxic receptors and then triggers apoptotic demise; (3) mAbs that binds 
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tumor-associated antigens (TAAs) and exerts dependent antibody-dependent 
cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis 
(ADCP), and complement-dependent cytotoxicity (CDC) through innate immunity; (4) 
immunoconjugates mAbs; (5) trifunctional or bispecific mAbs; and (6) mAbs that 
interfere with nutrient transfer between tumor cells and stroma [17][18][19][20]. 
Although, in recent years, oncology therapeutic mAbs are developed at a fast 
speed in preclinical and clinical trials, it remains common that antibodies do not alter 
tumor growth when treated with xenograft mice model. To improve the therapeutic 
effect, several approaches based on targeting cytotoxic agents on malignant tumor 
cells by conjugation with antibody have been developed, including antibody 
toxin-fusion proteins, antibody-drug conjugates (ADC), antibody enzyme conjugates, 
and antibody radionuclide conjugate [21]. 
1.4. Antibody-drug Conjugates  
 Pharmacological Mechanism of Antibody-drug Conjugate  1.4.1.
Antibody-drug conjugates are composed of three basic parts: highly selective 
antibody, linker, and cytotoxic small molecule drug. The structure of a typical ADC is 
shown in Figure 1. 
25 
 
 
  
 
 
 
Figure 1.2 Structure of typical antibody-drug conjugate 
The objective to accomplish a well-designed ADC is that an ADC preferentially 
delivers the cytotoxic small molecule drug only to tumor cells rather than to normal 
cells in order to improve the therapeutic index [22][23]. The mechanism by which 
ADCs disrupt tumor cells is by binding the specific mAbs to an antigen that is highly 
expressed only on the surface of tumor cells. After binding to the antigen, an 
ADC-antigen complex is formed, which is internalized into cells, and the cytotoxic 
drug is released, leading to cell death [23]. A typical mechanism of antibody-drug 
conjugates is shown in Figure 2.  
Antibody 
linker Drug 
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Figure 1.3 Typical mechanism of antibody-drug conjugates internalization 
 
 Design of Antibody-drug Conjugate  1.4.2.
Based on the mechanism described above, three key procedures need to be paid 
attention to when designing an ideal ADC: (1) antibody targets appropriate antigens 
and forms an ADC–antigen complex, (2) the stable linker prior to reaching the target 
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and releasing cytotoxic drug after internalization, and (3) the highly potent cytotoxic 
drug should exert its pharmacological effect after reaching the target. . The selection 
of an appropriate target, a stable linker, and a highly potent drug are discussed with 
reference to the design principle of ADC as follows. 
 Target 1.4.2.1.
An appropriate target selection should fulfill two criteria: high selectivity on 
tumor cells and high internalization efficiency.  
Most of the antigens express the same level on both normal cells and cancer 
levels, which makes it difficult for the related antibody to recognize the cancer cells. 
Therefore, an ideal target antigen should be expressed in higher copy numbers on the 
tumor cells (overexpress); this overexpressed characteristic, in part, contributes to 
ADC efficacy and tolerability [23][24]. For example, two 
ADCs—brentuximabvedotin (ADCETRIS) and trastuzumabemtansine 
(T-DM1)—have been shown to achieve distinct clinical activities with overexpressed 
target antigens on the tumor cells. ADCETRIS targeted antigen CD30 that is 
expressed on normal cells and strongly expresses in systemic anaplastic large-cell 
lymphoma (ALCL) and Reed–Sternberg cells of Hodgkin lymphoma (HL) tumor 
cells [25]. Similarly, T-DM1 targeted antigen, HER2, with normal expression in 
normal tissues, is highly overexpressed in some breast cancer tumors [26]. 
After binding to the antigen, the ADC conjugates with the antigen and forms an 
ADC–antigen complex, which is then internalized into the tumor cells—this process 
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is called as a receptor-mediated endocytosis. The extent and speed of internalization 
of an ADC is depended on the nature of cell-surface receptors. Some receptors, like 
transferrin receptors, continuously internalize without requiring binding with ligands, 
whereas, receptors like epidermal growth receptor accelerate the internalization rate 
after accumulate binding with their corresponding ligands [26]. In some cases, the 
internalization of an ADC is much more efficient than that of an unconjugated 
antibody [27][28]. 
 Linker 1.4.2.2.
A linker that connects monoclonal antibody with a cytotoxic drug binds through 
covalent linkage. The stability of a linker is important because it stays stable in the 
blood circulation while preventing damage to the non-target tissue, followed by 
release of the drug after reaching the target site [22]. There are two main types of 
linkers, including cleavable linker and non-cleavable linker; cleavable linker releases 
drugs by enzymatic reactions or hydrolysis after internalization, while non-cleavable 
linker releases drug through the degradation of antibody in the lysosome after ADC–
antigen complex internalization [23][24]. Table 1.1 lists some release mechanisms of 
important linkers. 
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Table 1.1 Release mechanisms of ADC linkers  
Linker Release mechanism 
Hydrazone 
Serum stable, degrade in acidic compartment within 
cytoplasm 
Peptide 
Enzymatically hydrolyzed by lysosomal protease like 
cathepsin B 
Disulfide  
Cleavage through disulfide exchange with an intracellular 
thiol 
Thioether Nonreducible, intracellular proteolytic degradation 
 
To optimize the solubility, the drug antibody ratio (DAR) and reduce the drug 
resistance (the protein that transports cytotoxic agents out of the cells) of ADCs, 
several strategies have been proposed including induce bystander effect and the use of 
polar linkers.  
Solid tumors express antigen heterogeneously, whereas, a positive 
antigen-specific ADCs only kills antigen-positive cells, which is ineffective in 
eradicating tumors. Therefore, an effective ADC should kill not only antigen-positive 
cells but also the surrounding cells through the bystander effect. Bystander effect 
depends on the charge of the linker-drug derivation released from ADCs, for example, 
the ADC brentuximabvedotin release neutral-charge MMAE, cross bio-membranes, 
and kill bystander epithelial cells, whereas ADCs based on MMAF release a charged 
metabolite, which is difficult to pass through bio-membranes and kill the neighboring 
cells. Reducible cleavable disulfide linkers can cross bio-membranes, while 
non-reducible thio-ether linkers cannot, which indicates that the ADCs with disulfide 
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linker have bystander cytotoxicity, while ADCs with thio-ether linker do not. 
MDR1 is a protein that transports hydrophobic cytotoxic agents out of cells, and, 
as a result, hydrophobic agents like ADCs with non-charged or non-polar 
maytansinoid linkers prove to have lower efficiency to MDR-positive cells. 
Development of an ADC with a polar or charged linker would not only overcome the 
adverse effect of MDR but also improve the solubility and therapeutic index. Because 
reducing hydrophobicity can slow down the clearance and enhance pharmacokinetics 
[25].  
 Cytotoxic Drug 1.4.2.3.
Low-potent cytotoxic agents such as doxorubicin and mitomycin used in the early 
ADC developments were found to be inefficient in inhibit solid tumor growth and 
showed lower accumulation in the target cells [29]. The reason for the failure of the 
conventional cytotoxic agent ADC could be attributed to only a limited number of 
antigens are expressed on the tumor surface, and the amount of drugs delivered to the 
tumor cell surface is low for a low drug to antibody ratio (DAR 3.5:4). Hence, only a 
limited number of novel highly potent cytotoxic agents with IC50 of 10-10-10-12M have 
been chosen to develop ADCs. Most of them target DNA or microtubule. The drugs 
targeting DNA are cytotoxic for both proliferating and non-proliferating cells, while 
drugs targeting microtubules are cytotoxic only for the proliferating cells [30]. When 
cytotoxic agents are chosen for developing ADCs, several factors should be 
considered, such as (1) most of the cytotoxic agents are hydrophobic, which can 
31 
 
 
  
induce antibody aggregation, and therefore lead to increased clearance rates and 
shortened validity [31]. (2) When a drug structure is modified for the linkage of the 
conjugate, the potency may decrease, and water solubility and stability may change 
[32]. Table 1.2 lists the current ADCs in clinical trials.  
 Auristatins and maytansionid are two typical groups of cytotoxic agents used 
in ADC developments. Auristatins have two derivatives: monomethyl auristatin E 
(MMAE) and monomethyl auristatin F (MMAF), which derived from the natural 
antimitotic agent dolastatin 10 and exerted their effects by inhibiting tubulin 
assembly.  
 In maytansinoid ADC, drugs used in the clinical trial are DM1 and DM4, 
which derived from natural benzoansamacrolide product maytansine, and it acts on 
tubulin. Due to its high toxicity, it has failed in clinical trials as an independent 
anticancer drug, but its stability and acceptable solubility make it a candidate for use 
as cytotoxic agent in ADC [33]. 
Other cytotoxic agents that have been used to develop ADCs include 
indolino-benzodiazepine, irinotecan derivatives, duocarmycins, 
pyrrolobenzodiazepines (PBDs), and tubulysins. Tubulysins are antimitotic peptides 
that inhibit microtubule polymerization during mitosis, which results in cell death. 
Duocarmycins is a DNA groove-alkylating agent. It binds to the minor groove of 
DNA and destroys it at a specific site [34][35]. PBDs, natural anticancer antibiotics 
that bind to the minor groove of DNA and destroy DNA in a specific sequence, are 
32 
 
 
  
now fast becoming as popular as ADCs development candidates for at least 10 ADCs 
based on PBDs have entered clinical trials.  
 
Table 1.2 ADC drugs in clinical stage 
 
Drug Target Linker Cytotoxic 
class 
Clinical stage 
Pinatuzumabvedotin CD22 VC MMAE Phase II 
(stopped) 
Indusatumabvedotin GCC VC MMAE Phase II 
(stopped) 
Vorsetuzumabmafodotin CD70 MC MMAF Phase I 
(stopped) 
Trastuzumabemtansine HER2 SMCC DM1 Entered market 
in 2013 
Mirvetuximabsoravtansine FOLR1 sulfo-SPDB DM4 Phase III 
Anetumabravtansine Mesothelin SPDB DM4 Phase II 
SAR428926 LAMP1 SPDB DM4 Phase II 
ADCT-301 CD25 PEG8-va SG3199 Phase I 
Rovalpituzumabtesirine DLL3 PEG8-va SG3199 Phase III 
IMGN779 CD33 sulfo-SPDB DGN462 Phase I 
Gemtuzumabozogamicin CD33 Hydrazone CM1 Approved in 
Japan 
Inotuzumabozogamicin CD22 Hydrazone CM1 Pre-registration 
Trastuzumabduocarmazine HER2++ vc–seco DUBA Phase I 
RC48-ADC HER2 VC MMAE Phase I 
Sacituzumabgovitecan TROP2 CL2A SN38 Phase III 
Vadastuximabtalirine CD33 
Engineered 
VA SGD1882 Phase III 
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  Other Optimized Approaches of Antibody-drug Conjugates  1.4.3.
Apart from selecting an appropriate antibody, linker, and cytotoxic agents, 
several additional approaches have been proposed to optimize ADC based on 
increased tumor penetration and antibody binding to inhibit immune checkpoints.  
Due to the poor penetration into solid tumors by antibody, there is a limit (0.001–
0.01% of injected amount per g) to which the cytotoxic agents can reach and target 
tumor cells in vivo [36]. Based on this limitation of ADCs, several new designs have 
been generated for the next generation ADCs, including (1) non-internalizing mAbs 
that link cytotoxic agents with disulfide linkers that are cleaved in a specific tumor 
extracellular microenvironment [37] and (2) Non-lgG scaffold includes designed 
Ankyrin Repeat Proteins (DARPins) [38]. Both design approaches demonstrated 
improved pharmacological and therapeutic performance.  
Another attractive way to improve the potency of ADCs is by combining it with 
immune-oncology antibodies. Antibodies that target immune checkpoint inhibitors 
like programmed cell death protein 1 (PD1), programmed cell death 1 ligand 1 
(PDL1), and immune responses like cytotoxic T lymphocyte 4 (CTLA4) have 
surprising efficiency on a series of tumor types. Checkpoint inhibitors activate 
immune responses without antigen-specific, seems to be active in a variety of tumors 
mutations, meanwhile, some cytotoxic agents used in ADCs have been shown to 
induce the death of immunogenic cells and induce activation and maturation of 
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dendritic cells. Hence, a combination therapy by immune-checkpoint inhibitors with 
ADCs that increase the immune response may have spectacular effect on oncology 
therapy [39]. 
1.5. Peptide-drug Conjugates 
Peptide-drug conjugates (PDCs), like ADCs, are another class of prodrugs. 
Targeting delivery of a drug to particular tumor-surface receptors is achieved by 
conjugating a drug to a specific sequence peptide. Peptide-drug conjugates are 
composed of three parts: drug, linker, and peptide (Figure 2). Due to the short length 
of peptide, PDCs are biodegradable and can avoid undesired immunogenic responses 
[40],[41]. The diversity of sequence made the diversity application of PDCs, while 
different sequences elicit different hydrophobicity and ionization, which could 
influence bioavailability both in vitro and in vivo. Other than ADCs, the low 
molecular weight of peptide allows PDCs high purification by using HPLC. Based on 
the difference in the characteristics of peptides, PDCs can be separated into two 
categories: Cell-targeting peptide drug conjugates and cell-penetrating peptide-drug 
conjugates. 
 
Figure 1.4 Structure of peptide-drug conjugate 
 
Drug Linker Peptide
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 Cell-targeting Peptide-drug Conjugates 1.5.1.
Tumor targeting peptide-drug conjugates are designed by using peptide with 
binding specificity to deliver the drug to particular tumor cells or tissues. The tumor 
targeting peptides were generated to target receptors expressed on the surface of the 
tumor vascular endothelial cell and cancer cell, or target to the tumor’s extracellular 
matrix [42]. The following sessions list some categories of cell-targeting peptides that 
have been used to developed peptide-drug conjugates. 
 IntegrinTtargeted Peptide–drug Conjugates 1.5.1.1.
Integrins are a family of proteins that are widely used as receptors because they 
are widely expressed in numerous cells. They play vital roles in physiological 
development, maintenance, repair of tissues, and pathological process in diseases, 
especially in cancer [43]. In the past two decades, integrin-targeted peptide-drug 
conjugates have been developed based on the wide distribution of αvβ3 targeting 
Arg-Gly-Asp (RGD) motif. Our group previously reported the potential of using 
modified RGD peptide amphiphiles to deliver hydrophobic drug like methotrexate, 
paclitaxel [42][44][45][46]. The Wadih group [47] conjugated RGD4c to doxorubicin, 
displaying enhancement of tumor inhibition and less toxicity of PDC to the liver and 
the heart compared with free doxorubicin. Another research group proved that when 
conjugated to integrin-targeting peptides, doxorubicin is preferentially released in 
tumor cells, which explains the unknown problem that the reported effect stems from 
the PDCs or the released doxorubicin. Except doxorubicin (DOX), paclitaxel (PTX) 
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and camptothecin (CPT) have also been used to conjugate with integrin-targeting 
peptides, both of which reveal high antitumor effect than free drugs in in vitro studies 
[48][49][50]. 
 Hormone Analog Peptide-drug Conjugates 1.5.1.2.
Hormone receptors like gonadotropin-releasing hormone (GnRH) receptor and 
somatostatin receptors are particularly overexpressed on the membrane of tumor cells 
[51]. Gonadotropin-releasing hormone (GnRH) receptor also named luteinizing- 
hormone-releasing hormone (LHRH) receptor is not expressed in critical organs. 
LHRH are being developed as conjugated to selectively deliver cytotoxic agents to 
cells expressing LHRH receptors [52]. Liu et al. conjugated luteinizing 
hormone-releasing hormone (LHRH) agonist AEZS-108 with anti-cancer agent, 
doxorubicin to targeted deliver doxorubicin selectively to prostate cancer CTCs, 
which has entered into clinical phase I study [53]. Tomas Vanek successfully 
developed targeted delivery system by conjugating mitotic inhibitor Paclitaxel and 
GnRH analog peptide (pGlu–His–Trp–Ser–Tyr–Gly–Leu–Arg–Pro–Gly·NH2) [54].  
Somatostatin, also known as growth hormone- inhibiting hormone, is a cyclic 
polypeptide that controls endogenous inhibitory [55]. Somatostatin is broadly 
distributed in the nervous system, regulates cell proliferation and division by directly 
activating somatostatin receptors [56]. The somatostatin belongs to G protein-coupled 
receptors family, and there are five subtypes of somatostatin have been identified. 
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Among them, somatostatin receptor-2 is preferential overexpressed in many tumors 
and tumor blood vessels. Hence, most of the somatostatin analog conjugates were 
developed to target to somatostatin receptor 2 site [57]. Huang et al. produced 
paclitaxel conjugate with somatostatin analog octreotide via a succinate linker[58]. 
This taxol octreotide conjugate was found to trigger apoptosis of somatostatin 
expression cells MCF-7 [58].  
 Other Cell-targeting Peptide-drug Conjugates 1.5.1.3.
In addition to RGD peptides and hormone analog peptides, other cell-targeting 
peptides were studied to develop new peptide-drug conjugates. EphA2 is 
tumor-targeting receptors that observed overexpressed on the surface of specific solid 
tumor cells including breast, prostate, and pancreatic. Ahmed F. Salem et al. 
generated peptide-drug conjugate by coupling EphA2-targeting peptide 123B9 with 
paclitaxel [59]. In breast cancer models, EphA2-targeting PDCs were found to 
efficiently inhibit carcinoma metastasized to the lung. PDCs that target to HER2 
receptors was performed, Tai group utilize HER2 targeting peptide KCCYSL linked 
to anticancer agent TGX-221 via self-cyclizing linkage. The conjugate turned out to 
specified bind to the HER2 receptor expressed on prostate cancer cells surface and 
provide a promising treatment strategy for prostate cancer [60]. 
 Cell-penetrating Peptide-drug Conjugates 1.5.2.
Cell penetration peptides (CPPs) are types of peptides that are able to cross the 
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mammalian cell membrane through the receptor-independently way. The rapid speed 
that CPPs enter into cells made CPPs attractive cargo to deliver therapeutic agents 
like a drug, DNA to the various situation and biological system [61]. Marco Lelle 
group synthesized two doxorubicin cell-penetrating peptide conjugates through 
hydrazone linker. The cellular uptake and distribution were assessed in MCF-7 and 
HT29 cell lines, and the increased toxicity on breast cancers has been observed on 
both two PDCs compared to HT29 cells [62]. Duan group developed two paclitaxel 
(PTX) cell-penetrating peptide conjugates PTX-TAT and PTX-LMWP. The enhanced 
antitumor potency was observed in tumor-bearing mice [63]. The anticancer agent 
gambogic acid (GA) has been developed to link with cell penetration peptide TAT. 
The improved solubility and induced EJ bladder cell uptake, toxicity and apoptosis 
were observed, which provide a promising used in bladder cancer therapy [64]. 
1.6. Anticancer Peptides (ACPs) 
In addition to conjugating anti-tumor cytotoxic drug with targeting antibody or 
peptide, anticancer peptide has become new treatment option for the molecular target 
anticancer drug development. Anticancer peptides are mostly derived from 
antimicrobial peptides (AMPs), which are a part of the immune defense mechanism of 
several organisms. The reason that AMPs can be used as ACPs for cancer therapy is 
because of the same membrane characteristic (negative cell surface charge) of the 
cancer cell and bacterial cells [65][66]. ACPs can be divided into two categories: 
membranolytic and non-membranolytic [67].  
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The selectivity and toxicity of peptide with membranolytic mechanism are 
modulated by target membrane feature [68]. The first difference between cancer cells 
and normal cells is the negative charge in the membrane disperse anionic molecules 
like phospholipid phosphatidylserine (PS), sialylated gangliosides, and 
O-glycosylated mucins in the membranes of cancer cells, resulting in a contrasting 
negative charge compared to the normal mammalian cell. Another difference between 
cancer cells and normal cells is in the content of cholesterol, as normal cell 
membranes have a high content of cholesterol in order to protect the cell by 
modulating the cell fluidity and block the entry of cationic peptides while most cancer 
cell surface cannot [69].  
By this membranolytic mechanism, the peptide action events include permeation, 
swelling of mitochondria, and apoptosis [69]. Peptides regulate the tumor vasculature 
by blocking the receptors that on the angiogenic endothelial cells. The formation of 
tumor vasculature is perturbed via this non-membranolytic mechanism [70][71].   
There are a total of 202 anticancer peptides recorded in the APD databases. Table 
3 shows some of the anticancer peptides that possess anticancer activity. Peptides can 
also be divided into two main groups based on the tumor type: solid and 
hematological tumors.  
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Table 1.3 List of anti-cancer peptides 
Peptide name Sequence Anticancer 
activity 
Tumor type Cancer cell 
D-K6L9 LKLLKKLLK
KLLKLL 
Necrosis via 
membrane 
depolarization  
Solid, 
Hematological 
Human prostate 
NRC-03 GRRKRKWL
RRIGKGVKIIGG
AALDHL 
ROS 
production and cell 
membrane lysis 
with possible pore 
formation in 
mitochondria  
Solid Human breast 
NRC-07 RWGKWFKK
ATHVGKHVGKA
ALTAYL 
ROS 
production and cell 
membrane lysis 
with possible pore 
formation in 
mitochondria and 
Solid 
 
Human breast 
Polybia-MPI IDWKKLLDA
AKQIL 
 
Cell membrane 
disruption with 
probable pore 
formation 
Solid Human bladder 
and prostate 
Hepcidin-TH2-
3 
QSHLSLCRW
CCNCCRSNKGC 
 
Cell membrane 
lysis 
Solid Human cervix, 
hepatocellular 
carcinoma, 
fibrosarcoma 
Temporin-1CE
a  
FVDLKKIANI
INSIF 
 
ROS 
production, 
membrane 
disruption, calcium 
release,  
Solid Human breast 
Epinecidin-1 GFIFHIIKGLF
HAGKMIHGLV  
 
Cell membrane 
lysis mediated by 
necrosis inhibitory 
activity  
 
Solid Human lung, 
cervix, 
hepatocellular 
carcinoma 
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PTP7 FLGALFKAL
SKLL 
Apoptosis 
induction 
Solid Human lung, 
prostate, breast and 
hepatocellular 
carcinoma  
BEPT II  RAALAVVL
GRGGPR  
 
Apoptosis 
induction 
Solid Human 
prostate 
ERα17p PLMIKRSKK
NSLALSLT 
 
Apoptosis 
induction and 
massive necrosis 
Solid Human breast  
R7-KLA RRRRRRRGG
KLAKLAKKLAK
LAK 
 
Plasma 
membrane 
permeabilization by 
pore formation 
Hematological Human acute T 
cell leukemia 
BIM SAHBA IWIAQELRXI
GDXFNAYYARR 
Apoptotic 
resistance  
Hematological Human 
histiocytic 
lymphoma, chronic 
myelogenous 
leukemia, acute 
myeloid leukemia 
SK84 AAGAATTC
AGCCAGCTAGG
TGACTTG 
 
Membrane 
disruption 
Hematological Human 
leukemia, liver and 
breast 
LfcinB FKCRRWQW
RMKKLGAPSITC
VRRAF  
 
Apoptosis by 
direct disruption of 
the mitochondrial 
membrane 
Hematological Human acute 
lymphoblastic T 
leukemia, acute T 
cell leukemia 
 
 Lytic Peptide 1.6.1.
Lytic peptides are a group of bioactive cationic peptides that act on the surface of 
cell membranes and have strong anti-cancer activities [72]. As the multidrug 
Resistance (MDR) resulted in reduced efficiency in the cancer cells when treated with 
the cytotoxic agents, the development of lytic peptide is attractive for its ability to 
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bypass MDR mechanism by acting on the cell membrane [73].  
K6L9, a typical lytic peptide, induces cytolytic effect through these two steps: (1) 
membrane disruption and necrosis of tumor cells and (2) decrease in the tumor vessel 
density. It can inhibit the metastases for both solid tumor and hematological tumor 
when they are used in treatment in vivo [74]. By targeting with phospholipid 
phosphatidylserine (PS) expressed on the neoplastic cells, the peptide colocalizes with 
the negatively charged phospholipid and then elicits membrane-depolarizing lytic 
activity.  
Consider the lower extracellular pH in the solid tumor site as compared to the pH 
in the normal tissue site, the pH-sensitive lytic peptide has raised interest. Liang et al. 
[80] designed a pH-sensitive lytic peptide by modifying a known lytic peptide LL-1 
(FLGALWKALSKLL) with histidine (H) amino acid, and then found more 
pH-sensitive activity on histidine-containing peptides LL-1a, LL-1b, and LL-1c 
(FLGALWHALSKLL, FLGALWKALSHLL, FLGALWHALSHLL) [73]. Another 
advantage of histidine-containing peptides represents improved stability and half-lives 
(up to 11 h) [72]. 
 
 Hybrid peptide 1.6.2.
Although lytic peptide has its selectivity for tumor cells, a new strategy has been 
proposed, wherein antigen-targeting peptide is combined with lytic peptide to form a 
hybrid peptide for use in assessing the better selectivity and cytotoxic activities in 
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vitro and in vivo. In 2013, Kawakami et Al. [75]designed a HER2-lytic hybrid peptide 
by linking the HER2-binding moiety peptide KCCYSL and a newly designed lytic 
peptide KLLLKLLKKLLKLLKKK (bold letters indicate D-amino acids) and 
achieved significant inhibition of HER2 receptors and block the HER2 signal in the 
HER2 overexpressing cell lines. In vivo studies also proved the efficiency of 
HER2-lytic hybrid peptides [75]. In 2016, the Kawakami group [76] prepared a new 
hybrid peptide based on the EGFR binding moiety, that is, EGFR-lytic hybrid peptide, 
which elicited cytotoxic effect on the pathophysiology of esophageal squamous cell 
carcinoma. Table 1.4 shows some of the hybrid peptides that have been developed. It 
is worth suggesting that conjugating hybrid peptide with cytotoxic drug may help 
reverse drug assistance and induce efficiency of cytotoxic agents. 
 
Table 1.4 List of hybrid peptides 
Target Target peptide Lytic peptide Hybrid peptide 
EGFR YHWYGYTPQNVI 
 
KLLLKLLKKLLK
LLKKK 
 
YHWYGYTPQNVIGGGKL
LLKLLKKLLKLLKKK 
 
HER2 KCCYSL KLLLKLLKKLLK
LLKKK 
 
KCCYSLGGG 
KLLLKLLKKLLKLLKKK 
 
αvβ3  
 
CIRTPKISKPIKFELS
G 
 
SKKPVPIIYCNRRS
GKCQRM 
GSKKPVPIIYCNRRSGKCQ
RMGSIRTPKISKPIKFELSG  
[78] 
TfR HAIYPRH 
 
MPKKKPTPIQLNP 
 
HAIYPRHGGCGMPKKKPT
PIQLNP [79] 
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1.7. Human Epidermal Growth Factor Receptor 2 
The ErbB family is a group of proteins containing four receptor tyrosine kinases, 
including epidermal growth factor receptor (EGFR), HER2 (ErbB2), HER3 (ErbB3), 
and HER4 (ErbB4). The ErbB receptors play an important role in human cancers 
because they are expressed in multifarious tissues of epithelial and neuronal origin 
[77]. After ligand binding with the receptor, the pathways will be activated. 
Consequently, the cancer cells show higher proliferation, survival, migration, and 
differentiation potential [78][79].  
The human epidermal growth receptor 2 oncogene encodes a receptor tyrosine 
kinase that is overexpressed in >20% of human breast cancer cases [80]. HER2 has 
become a suitable target candidate for molecular target cancer therapy. Humanized 
recombinant monoclonal antibodies that inhibit HER2 receptors have also been 
developed, including trastuzumab and pertuzumab, which have been used for the 
treatment of HER2-positive breast cancers [81]  
Except antibodies, peptides that target HER2 receptor tyrosine kinase have also 
been developed. Table 5 shows the HER2-targeting peptides derived from the phage 
display library. 
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Table 1.5 Sequence of HER2-targeting peptides 
Peptide sequence Library Referen
ce 
AC#SLQDPNC#DWWGHYC#G (H8)c ACX6CX6CG [88] 
ACGLQGYGCWGMYGKCG (H30)c ACX6CX6CG [88] 
CVGVLPSQDAIGIC (L-26-19)d Ph.D.-12 [89] 
CGPLPVDWYWC (L-26-24)d Ph.D.-12 [89] 
CEWKFDPGLGQARC (N-12-1)e Ph.D.-12 [89] 
CDYMTDGRAASKIC (N-12-2)e Ph.D.-12 [89] 
KCCYSL 6mer [90] 
MARSGL, MARAKE, MSRTMS 6mer  [91] 
LTVSPWY Ph.D.-7 [92][93] 
WTGWCLNPEESTWGFCTGSF (EC-1) 20mer [94] 
 
1.8.  Statement of the Problem 
In the background section, we have listed novel target-delivery system and 
among them, the HER2-targeted antibody-drug conjugate Kadcyla (trastuzumab 
emtansine) was developed and approved by FDA in 2014. However, the poor 
penetration in solid tumor, the high manufacturing cost, and long development cycle 
limits the extensive development of antibody–drug conjugates. Compared to the 
antibody, peptides with flexible structure and low molecular weight are becoming a 
promising target agent for application in the target delivery system. 
1.9. Hypothesis 
Designed HER2-targeting peptide–drug conjugates and hybrid peptides could 
exhibit highly selective cytotoxicity for HER2 overexpressed breast cancer cells.  
1.10. Specific Aims 
The objective of this research is to design the potent peptide–drug conjugates and 
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hybrid peptides that provide a prospective chemotherapy strategy for breast cancer 
patients. In order to achieve this objective, the following specific aims have been 
established:  
1. To synthesize HER2-targeted peptides using solid phase synthesis method on 
Wang resin. 
2. To study the in vitro binding specificity of Her2-targeted peptides and 
cysteine-modified peptides. 
3. To design and synthesize peptide–drug conjugates with a non-cleavable linker 
maleimidocaproyl (MC) and MMAE.  
4. To design and synthesize peptide–drug conjugates with a cleavable linker 
maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl (MC-VC-PAB) 
and MMAE 
5. To synthesize hybrid peptides with a cytolytic peptide Melittin 
(GIGAVLKVLTTGLPALISWIKRKRQQ). 
6. To purify and characterize peptides and peptide–drug conjugates. 
7. To study the cytotoxic potency of synthetic peptide–drug conjugates and hybrid 
peptides. 
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CHAPTER 2:  SYNTHESIS AND CHARACTERIZATION OF PEPTIDES 
 
2.1. Introduction 
A typical peptide synthesis requires the formation of amide bond, provided and 
formed by the amino and carboxyl groups of two amino acids. However, numerous 
possibilities of combinations of amino acids made the synthesis of peptide more 
complicated than forming a simple amino acid. Solid-phase peptide synthesis (SPPS) 
technique was developed in 1962 by Bruce Merrifield in order to provide an effective, 
rapid, and simplified method for the preparation of peptides and small proteins. The 
basic concept of SPPS is the step-wise construction of a peptide chain attached to an 
insoluble polymer substrate. The insoluble polymers used for SPPS also named resins. 
Different resins can be used to synthesize various peptides. For example, Wang resin 
is conventional resin for Fmoc/tBu SPPS; DHPP Resin is developed especially for 
peptides with C-terminal proline; PDDM-resin is applied for peptides containing 
C-terminal Cys or His. 2-Chlorotrityl is an acid-labile resin. This resin is suitable for 
synthesizing peptides containing a C-terminal Cys or Pro. [82]. The insoluble polymer 
resin attached to the carboxyl group of the terminal amino acid conjugates to the next 
amino acids protected by the Fmoc group. After coupling, the Fmoc acid protection 
group is removed from the chain in order to provide a free amino group for coupling 
the next amino acid. The peptide chain is extended by the duplication of synthesis 
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cycle. The polymer resin and the side-chain protection group must be removed prior 
to the cleavage of resulting peptide by using a 95% solution of trifluoroacetic acid 
(TFA). 
The purpose of this chapter is to utilize solid phase peptide synthesis technique to 
synthesis HER2 targeting peptides for binding specificity study and PDC synthesis. 
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Figure 2.1 Mechanism of piperidine de-protection 
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Figure 2.2 Mechanism of coupling  
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Figure 2.3 Mechanism of cleavage 
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Figure 2.4 Mechanism of synthesis FITC-labeled peptide 
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2.2. Materials 
Fmoc-Wang resins, N-hydroxybenzotriazole (HOBT), 
N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uranium hexafluorophosphate 
(HBTU), triisopropylsilane (TIS) were obtained from Chem-Impex International Ltd. 
(Wood Dalw, IL, USA). Acetonitrile (ACN), dichloromethane (DCM), and 5-FITC 
were purchased from Fisher Scientific (Pittsburgh, PA, USA). Diisopropylethylame 
(DIPEA), tert-butyl methyl ether, trifluoro acetic acid (TFA), and 
N,N’-dimethylformamide (DMF) were obtained from Axros Organics (New Jersey, 
USA). All amino acids used in the SPPS were purchased from Anaspec Int. (Fremont, 
CA) 
2.3. Methods 
 Synthesis of Peptides 2.3.1.
Peptides were synthesized by SPPS with Fmoc chemistry on Wang resin (0.2 
mmol) and coupled amino acids (1 mmol) with DIPEA (1.8 mmol), HBTU (1 mmol), 
and HOBT (1 mmol). After coupling for 2.5 h at the room temperature, Kaiser test 
was performed to ensure the completion of the reaction. Fmoc group deprotection 
solution was prepared with 20% piperidine in DMF. Peptide cleavage cocktail was 
performed with phenol (0.33 g), deionized water (330 µL), TIPS (60 µL), and TFA 
(5.7 mL). After shaking for 3 h at the room temperature, the TFA solution was cooled 
and collected by using nitrogen. The peptide was then precipitated by adding cold 
tert-butyl methyl ether. The resultant peptide precipitate was washed three times with 
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cold ether, dissolved in water, and then lyophilized overnight. 
 Synthesis of FITC-labeled Peptides 2.3.2.
The 6-aminohexanoic acid protected with Fmoc was coupled to peptide with 
resin by using the same method as that for regular amino acid. 5-FITC (0.3 mmol) 
was conjugated with peptide (0.1 mmol) in anhydrous DMF solution catalyzed with 
DIPEA (1.2 mmol). The reaction was performed at the room temperature for 12 h in 
dark. The FITC-labeled peptide was removed from the resin by using the same 
cocktail as mentioned above and following the same washing, precipitating, and 
lyophilizing procedures used in 2.3.1. Dried FITC-labeled peptide was stored at -20°C 
for further use. 
 HPLC Analysis and Purification 2.3.3.
The peptides and FITC-labeled peptides were analyzed by reverse-phase 
high-pressure liquid chromatography (HPLC) using the Agilent 1100 System with 
Agilent Zorbax SB-C18 (4.6 x 150 mm, 3.5 µm column) at 210 nm and 230 
wavelengths. The mobile phase solvents were water (solvent A) and acetonitrile 
(solvent B), and both the solvents were used with 0.1% TFA. Elution was performed 
with a liner gradient for 30 min from 5% to 95% solvent B at the flow rate of 1 
mL/min. The peptide was purified by collecting the eluting peak, lyophilizing, and 
then storing at -20°C for further use. 
2.3.4. Characterization of Peptides  
The peptides were characterized by using the Electro Spray Ionization Mass 
55 
 
 
  
Spectrometry (ESI-MS; AB Sciex PI 3000 Ion Trap Mass Spectrometer, SCIEX, CA, 
USA) . The samples were prepared in acetonitrile and water mixtures and were 
infused at the speed of 10 µL/min. Ion source parameters are listed as follows: 
Nebulizer Gas (NEB) 8 Psi,  IonSpray Voltage 5500 V; TEM （Temperature） 300℃; 
CUR （Curtain Gas） 8 Psi. 
2.4. Results and Discussions 
Peptides were successfully synthesized using SPPS technique. To make the 
coupling reaction more efficient, a potent coupling agent, a mixture of HOBT, HBTU, 
and DIPEA, was used. Fluorescent-dye FITC was conjugated with the peptides for 
confocal studies. The peptide cannot be directly linked to the FITC because of the 
unstable abilities of conjugates. To prolong the stability of the conjugates, a spacer, 
6-amino hexanoic acid, was attached to the N-terminus of the peptide and then 
conjugating FICT on the spacer.  
The HPLC peaks of all peptides were observed at around 8–9 min (Figures 2.15 
to 2.18). HPLC peaks of FITC-conjugated peptides were observed at 15–16 min 
(Figures 2.19 to 2.22). Different peaks were collected to identify and confirm the 
molecular weights of peptides and FITC-labeled by MS. All the peptides were 
characterized using ESI MS. The MS results revealed the expected molecular weight 
of the peptides and FITC-labeled peptides. The MS confirmed the formation of all 
peptides and FITC-labeled peptides molecules as shown in Figures 2.5 to 2.14 and 
table 2.1. 
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HER2 targeting peptides and cysteine modified HER2 targeting peptides were 
successfully synthesized for the further peptide binding specificity study and 
peptide-drug conjugates synthesis. 
The HER2 targeting peptide has been reviewed in 1.7. Among the peptides listed 
above, the peptide MARAKE and MARSGL have been chosen to develop 
peptide-drug conjugates. These 6-mer peptides with published binding constant (KD) 
value 10 nM [83], were ideal candidates to for PDC synthesis. The equilibrium 
binding constant (KD) is generally used to determine the binding affinity between the 
ligand and the receptor. Binding affinities are used to determine the strength of 
binding of a single molecule to its receptors. The KD value relates to the 
concentration of antibody. The lower KD value represents the higher affinity of the 
antibody or antibody mimic. Peptides cannot be used directly to conjugate to drugs 
without linkage.  
 In our study, the reaction between peptides and linker rely on a thiol group 
reacting with the maleimide group, which will be further discussed in Chapter 4. 
Thiol group was provided by cysteine in the peptide, while maleimide group comes 
from maleimidocaproyl to form the linker. As described above, cysteine modified 
peptides (MARAKEC, MARSGLC) have been synthesized for PDC synthesis. 
To further prove the binding specificity of the chosen HER2 targeting peptide and 
cysteine modified HER2 targeting peptides, FITC-labeled peptides were synthesized 
for immunofluorescence in-vitro study. Scramble peptide (MAKRAE) and 
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FITC-labeled scramble peptide were developed as the negative control in 
immunofluorescence study. 
All peptides were successfully synthesized by SPPS. FITC was conjugated to the 
peptides at the N-terminus. All peptides molecules were characterized by MS and 
purified by RP-HPLC for use in further experiments. 
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Table 2.1 Sequence of synthesized peptides  
Peptides Structure HPLC Purity MW 
ER1 MARAKE 94.00% 704.84  
FITC-ER1 MARAKE-FITC 96.00% 1206.00  
ER1C MARAKEC 95.00% 807.99  
FITC-ER1C MARAKEC-FITC 99.90% 1309.99  
ER2 MARSGL 97.00% 633.76  
FITC-ER2 MARSGL-FITC 99.80% 1135.76  
ER2C MARSGLC 96.00% 736.91  
FITC-ER2C MARSGLC-FITC 96.10% 1238.00  
RA1 MAKRAE 94.00% 704.84  
FITC-RA1 MAKRAE-FITC 95.10% 1206.00  
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Figure 2.5 The ESI-MS spectrum of peptide ER1 
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Figure 2.6 The ESI-MS spectrum of FITC-labeled peptide ER1 
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Figure 2.7 The ESI-MS spectrum of peptide ER1C 
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Figure 2.8 The ESI-MS spectrum of FITC-labeled peptide ER1C 
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  Figure 2.9 The ESI-MS spectrum of peptide ER 
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  Figure 2.10 The ESI-MS spectrum of FITC-labeled peptide ER2 
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  Figure 2.11 The ESI-MS spectrum of peptide ER2C 
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Figure 2.12 The ESI-MS spectrum of FITC-labeled peptide ER2C 
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Figure 2.13 The ESI-MS spectrum of peptide RA 
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Figure 2.14 The ESI-MS spectrum of FITC-labeled peptide RA 
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Figure 2.15 The HPLC chromatogram of peptide ER1 
 
 
 
 
Figure 2.16 The HPLC chromatogram of peptide ER1C 
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Figure 2.17 The HPLC chromatogram of peptide ER2 
 
 
 
 
 
Figure 2.18 The HPLC chromatogram of peptide ER2C 
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Figure 2.19 The HPLC chromatogram of FITC-labeled peptide ER1 
 
 
 
Figure 2.20 The HPLC chromatogram of FITC-labeled peptide ER1 
 
 
Figure 2.21 The HPLC chromatogram of FITC-labeled peptide ER2 
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Figure 2.22 The HPLC chromatogram of FITC-labeled peptide ER2C 
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CHAPTER 3:  BINDING SPECIFICITY OF HER2-TARGETING PEPTIDE 
 
3.1. Introduction 
The signaling pathway in cells starts from the binding of ligands and receptor. 
Ligand and receptor come in closely matched pairs, with receptors recognizing 
specific ligands. Another similar signaling pathway is antibody-antigen interaction. 
The antibody specifically binds to the antigen expressed on the surface of cells. After 
binding with an antigen, the antibody-antigen complex is transported into cells. The 
design of antibody-drug conjugates utilizes this characteristic of antibody and antigen 
complex. By linking the drug to an antibody, the conjugate can deliver the drug to the 
specific target cancer cells. The specificity of antibody leads to high potency and low 
cytotoxicity of antibody-drug conjugate, the same concept can be applied to the 
peptide-drug conjugates.  
Immunofluorescence (IF) is a conventional laboratory technique used to identify 
microbiological samples with a fluorescent microscope. This technique is used for 
studying specificity of antibodies binding to a specific antigen by monitoring 
fluorescent dyes in specific bio-molecular targets or cells. Immunofluorescence 
labeled antibody can recognize and stain particular cellular protein. The specificity of 
the antibody-fluorescence conjugation can be verified by using cell line with known 
expression target or level. The specificity of peptides can be determined by similar 
method with the use of fluorophore-conjugated targeting peptides. HER2 is 
74 
 
 
  
overexpressed in breast cancer cell lines, and it undergoes receptor-mediated 
endocytosis when trastuzumab binds to HER2. To evaluate the peptides’ binding 
specificity to HER2 receptor, confocal and fluorescent microscopy was used with 
5-FITC conjugated HER2-targeting peptides. Fluorescent microscopy showed the 
binding specificity, while confocal microscopy confirmed the internalization of the 
samples. 
The purpose of this chapter is using immunofluorescence to verify the specificity 
of HER2-targeting peptide. 
3.2. Materials 
The Alexa Fluor 594 wheat germ agglutinin SlowFade were obtained from 
Invitrogen (Carlsbad, CA, USA). Formaldehyde (4%) in PBS was purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). All chemicals and solvents 
were used without purification. PBS was ordered from Gibco (Invitrogen Corporation, 
Japan).  
The MDA-MB 361, ZR 75, and HEK 293 cells were purchased from ATCC 
(Manassas, VA, USA). Dulbecco’s modified eagle medium (DMEM), 4.5 g/L glucose, 
L-glutamine and 1% penicillin-streptomycin (5000 I.U./mL) were obtained from 
Mediatech (Manassas, VA, USA). Sodium pyruvate containing 10% heat-inactivated 
fetal bovine serum was ordered from Gemini (Sacramento, CA, USA) 
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3.3. Methods  
The MDA-MB 361, ZR 75, and HEK 293 cells were cultured in 75-cm2 culture 
flasks in DMEM supplements with 10% FBS and 1% penicillin-streptomycin. Cells 
(1 x 105) were placed on cover slips in 6-well plates and cultured at 37 °C for 24 h. 
The mediums were removed from 6-well plates. The cells were then washed with 
PBS and serum-free media. FITC-labeled peptides were used to treat cells in the 
serum-free media for 20 min. Then, the medium was removed, and the cells were 
washed with PBS twice in order to remove the unbound peptides. Alexa Fluor 594 
wheat agglutinin (2.5 µg/mL in PBS) was then used to treat cells for 10 min to stain 
the cell membranes. The cells were washed two times with PBS and fixed with 4% 
paraformaldehyde for 15 min. The cover slips were attached to the slides with a drop 
of SlowFade antifade reagent. The cells were then imaged under brand BZ-X710 
All-in-One Fluorescence Microscope (Keyence, Itasca, USA) using green and red 
filters with 40 X objective. The samples prepared for fluorescence microscope were 
also used for visualization by an inverted Leica DMIRE2 confocal microscope (Leica 
Microsystems GmbH, Germany) with Yokogawa CSUX1 63X magnification 
(Yokogawa Electric Corporation, Japan) to verify internalization. All the images were 
analyzed and transformed to the bmp format by Image J software. 
3.4. Result and Discussion 
Ligand binding assays (LBA) is an analytical assay used to measure the strength 
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of ligand binding to receptors. Numerous techniques are used to measure the ligand 
binding including fluorescence resonance energy transfer (FRET), fluorescence 
polarization (FP), and surface plasmon resonance (SPR). In this study, the specificity 
of HER2-targeting peptides has been confirmed. HER2 specific - peptides should 
preferentially bind to tumor cancer cells that over express HER2 rather than to normal 
cells. Binding specificity studies are used to determine the specific binding and uptake 
of different molecules in the target cells. Confocal and fluorescent images provide the 
visual information about the peptides binding to target cells. To determine the 
influence of cysteine added in peptide sequence, four specific peptides ER1 
(MARAKE), ER1C (MARAKEC), ER2 (MARSGL), ER2C (MARSGLC), and one 
random peptide RA (MAKRAE) were chosen to study the binding specificity.  
Three different cell lines were used to study the binding specificity of peptides. 
MDA-MB-361 cells and ZR-75-1 cells are cell lines that overexpress HER2, while 
HEK293 cells are the human normal kidney cells that do not express HER2 [84]. All 
four FITC-labeled peptides and cysteine-modified peptides were found to be 
specifically bound to the cell membrane and internalized into the cells that 
overexpressed HER2 within the first 20 min at 37˚C. As shown in Figure 3.1- Figure 
3.4, significant higher fluorescence was observed in MDA-MB 361 and ZR 75-1 cells 
as compared with the negligible fluorescence found in HEK 293 cells, which 
demonstrated the binding specificity of the four specific peptides towards HER2. In 
the case of FITC-labeled control peptide RA1, no binding was observed in all of three 
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cell lines. The binding specificity of the ER1 and ER2 peptides confirmed the claim in 
the literature [83], and the binding specificities of cysteine-modified peptides were 
also proved. The result of the confocal microscopy studies suggested that 
cysteine-modified peptides retain their binding capability to HER2-positive cell lines. 
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Figure 3.1 Confocal images of peptide ER1. Alexa Fluor594 column represents 
the cell treated with membrane dye, FITC-PEP-MARAKE displays the cells treated 
with FITC conjugated peptide and overlap column represent the merge of the two 
images. 
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Figure 3.2 Confocal images of peptide ER1C. Alexa Fluor594 column represents 
the cell treated with membrane dye, FITC-PEP-MARAKEC displays the cells treated 
with FITC conjugated peptide and overlap column represent the merge of the two 
images. 
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Figure 3.3 Confocal images of peptide ER2. Alexa Fluor594 column represents 
the cell treated with membrane dye, FITC-PEP-MARSGL displays the cells treated 
with FITC conjugated peptide and overlap column represent the merge of the two 
images. 
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Figure 3.4 Confocal images of peptide ER2C. Alexa Fluor column represents the 
cell treated with membrane dye, FITC-PEP-MARSGLC displays the cells treated with 
FITC conjugated peptide and overlap column represent the merge of the two images. 
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Figure 3.5 Confocal images of peptide RA. Alexa Fluor594 column represents 
the cell treated with membrane dye, FITC-PEP-MAKRAE displays the cells treated 
with FITC conjugated peptide and overlap column represent the merge of the two 
images. 
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CHAPTER 4:  SYNTHESIS AND CHARACTERIZATION OF 
PEPTIDE-DRUG CONJUGATES AND HYBRID PEPTIDES 
 
4.1. Introduction 
As stated in Chapter 1, peptide–drug conjugates share similar concepts with 
antibody–drug conjugates; the flexibility of PDCs in structure and low molecular 
weight lead to enhanced drug loading and higher penetration into the solid tumor 
tissues. The peptides used in PDCs can be divided into two categories: cell 
penetration peptides (CPPs) and cell-targeting peptides (CTPs). The linker used in 
PDCs can be categorized into two types: non-cleavable linkers and cleavable linkers. 
Carbon chain, amide bond, and ether bond are commonly used in non-cleavable linker 
designs. They are stable in biological fluids and can reduce the premature drug release 
in the blood circulation. PDCs with the cleavable linkers can release the drug after 
reaching the tumor site. The cleavable linkers can be further divided into three 
different types: pH-sensitive, redox-sensitive, and enzyme-sensitive. Hydrazone bond, 
vinyl ether bond, and acetal bond are pH-sensitive linkers that release drug in an 
acidic environment in the endosomes. Redox-sensitive linkers release the drugs in 
endosomes mediated by GSH. The cleavage of the enzyme-sensitive linkers are 
mediated released drug by Cathepsin B. For the objective of this study, 
HER2-targeting peptides MARAKE and MARSGL were chosen as targeting moiety 
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to design the peptide–drug conjugates. Two type linkers: non-cleavable 
Maleimidocaproyl (MC) linker and cleavable valine-citrulline (VC) linker were used 
to link the cytotoxic drug MMAE and targeting peptides to form the peptide–drug 
conjugates. 
Cytolytic peptides, which emerge from eukaryotic cells, were found to have 
anticancer function. In this study, a design based on the fusion of cytolytic peptide as 
anticancer agent and HER2 binding peptide was carried out to generate a 
“peptide-peptide conjugate” for targeted cancer delivery of cytolytic peptide [84]. In 
our study, a lytic peptide, melittin [67] that was developed from nanobees was chosen 
to fuse with HER2-targeting peptide in order to form hybrid peptides. Table 4.1 
indicates the design of hybrid lytic peptides. When cytolytic peptides are used in the 
design, non-cleavable amid linkage is used. 
The purpose of this chapter is to synthesize, characterize and purify peptide-drug 
conjugates and hybrid peptides for in vitro studies.  
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Figure 4.1 Structure of MMAE（1） 
 
 
 
 
 
 
 
 
Figure 4.2 Mechanism of peptide–drug conjugates reaction 
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Figure 4.3 Structure of PDC based on MC-MMAE (2). The linker consisting of 
attachment group maleimidocaproyl is marked by red. The drug MMAE is blue while 
the peptide is green. 
 
 
 
 
Figure 4.4 Structure of PDC based on VC-MMAE (3). The linker consisting of 
cleavable dipeptide valine (Val)-citrulline(Cit), the spacer (p-aminobenzylcarbamate) 
and the attachment group maleimidocaproyl. The dipeptide is marked by yellow; the 
spacer is pink; the attachment group is red; the color of drug MMAE and the peptide 
are the same as Figure 4.3. 
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Table 4.1 Summary designing of peptide-drug conjugates 
Name of PDCs  Peptide Linker 
YW1 (4) MARAKEC MC-MMAE (2) 
YW2 (5) MARSGLC MC-MMAE (2) 
YW3 (6) MARAKEC VC-MMAE (3) 
YW4 (7) MARSGLC VC-MMAE (3) 
 
 
 
 
 
Table 4.2 Sequence of lytic peptide and hybrid peptides 
Peptides Structure MW 
LY1 (8) GIGAVLKVLTTGLPALISWIKRKRQQ 2847.46 
HY1 (9) MARAKE-GGG-GIGAVLKVLTTGLPALISWIK
RKRQQ 
3705.44 
HY2 (10) MARSGL-GGG-GIGAVLKVLTTGLPALISWIKR
KRQQ 
3634.36 
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Figure 4.5 Model of Antibody-drug conjugate (a), peptide-drug conjugate (b), 
and hybrid peptide (c). 
4.2. Materials 
MC-MMAE and VC-MMAE were obtained from Boc Science (Shirley, NY, 
USA). MMAE was ordered from Medchem Express (New Jersey, USA), and 
N,N’-dimethylformamide (DMF) and Triethylamine (TEA) were purchased from 
Axros Organics (New Jersey, USA). 
4.3. Methods 
 Synthesis of MC-MMAE Peptide–drug Conjugate 4.3.1.
Peptide (1.1 eq) with a free thiol group and MC-MMAE (1 eq) were dissolved 
separately in DMF. The peptide was added to the MC-MMAE DMF solution 
drop-wise, to which 10 µL of TEA was added into the reaction mixture under 
nitrogen protection. The reaction mixture was stirred for 2.5 h at the room 
temperature and then evaporated under reduced pressure.  
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 Synthesis of VC-MMAE Peptide–drug Conjugate  4.3.2.
VC-MMAE was used in the place of MC-MMAE and other procedures and 
conditions were the same as that described in 4.3.1. 
 Purification of Peptide–drug Conjugate 4.3.3.
All peptide–drug conjugates were dissolved in methanol and then purified on 
RP-HPLC with the Agilent 1100 System (Agilent Zorbax SB-C18; 4.6 x 150 mm, 
3.5-µm column) at 230 and 280 nm. The mobile phase solvents were water (solvent A) 
and methanol (solvent B), and both solvents were used with 0.1% TFA.  Elution was 
performed with a linear gradient for 30 min from 5% to 95% solvent B at the flow 
rate of 1 mL/min at 23.8°C. 
 Characterization of Peptide–drug Conjugate 4.3.4.
The products were characterized by using Electro Spray Ionization Mass 
Spectrometry (ESI-MS; AB Sciex PI 3000 Ion Trap Mass Spectrometer). The samples 
were prepared in methanol and water mixtures and infused at the speed of 10 µL/min. 
Ion source parameters are listed as follows: Nebulizer Gas (NEB) 8 Psi, Ion Spray 
Voltage 5500 V; TEM （Temperature） 300℃; CUR （Curtain Gas） 8 Psi. 
4.4. Results and Discussion 
In this study, HER2-targeting peptide ER1 and ER2 were selected to synthesize 
peptide-drug conjugates. Cysteine was used to modify HER2-targeting peptides to 
generate a functional group for the linkage to the drug. The specificity of 
cysteine-modified peptide ER1C and ER2C were retained after modification as 
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confirmed in Chapter 3.  
These modified targeting peptides were conjugated with MMAE, which is a 
non-selective but potent tubulin polymerization inhibitor that develops high toxicity 
in tumor cells. Two type linkers: non-cleavable Maleimidocaproyl (MC) linker and 
cleavable valine-citrulline (VC) linker were used to prepare the peptide–MMAE 
conjugates. Both MC linker and VC linker have the maleimide group, which can react 
with the thiol group and form the thiol-ether bond between the peptide and the drug. 
The reaction mechanism of thiol group and maleimide group was illustrated in Figure 
4.2. 
All the intermediate and final products were characterized by ESI-MS as shown 
in Table 4.2. The mass spectra for MMAE, MC-MMAE, VC-MMAE, YW1, YW2, 
YW3, and YW4 were observed as both single- and double-charge species (Figures 
4.9–4.15). RP-HPLC was performed to check the purity and to purify the PDCs. The 
purity of all compounds was found to be >95% (Figure 4.5-4.8; Table 4.2). All PDCs 
were purified through RP-HPLC on the C18 column and used for further experiments. 
The lytic peptide and hybrid peptides were successfully synthesized and were 
characterized by ESI-MS as shown in Table 4.3. The mass spectra for LY1, HY1, 
HY2 were observed from quadruple to octuple charge (Figure 4.16-4.18). 
In this chapter, four peptide-drug conjugates were successfully synthesized and 
purified. ESI mass spectrum was used to characterize the molecular weight of 
conjugates, while HPLC was used to purify the conjugates. The purities of 
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peptide-drug conjugates were confirmed more than 95%.  Peptide with more than 90% 
purity also named high-level of purity peptide, which is beneficial for in-vitro 
cytotoxicity studies.  
The lytic and hybrid peptides were also successfully synthesized and 
characterized. However, the purities of lytic and hybrid peptides were range from 69% 
to 73%, which was considered in mid-range levels of purity. This level of purity is 
appropriate for screenings peptides in the preliminary studies. Lytic and hybrid 
peptides cytotoxicity studies were performed in Chapter 5.  
 
 
Table 4.2 MMAE, intermediates and PDC MS and HPLC data 
Molecule HPLC Purity (%) MW (g/mol) 
MMAE (1) 99% 718 
MC-MMAE (2) 99% 911.2 
VC-MMAE (3) 99% 1316.65 
YW1 (4) 98% 1720 
YW2 (5) 98% 1649 
YW3 (6) 99% 2124 
YW4 (7) 98% 2053 
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Figure 4.5 HPLC chromatogram of YW1 
 
Figure 4.6 HPLC chromatogram of YW2 
 
Figure 4.7 HPLC chromatogram of YW3 
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Figure 4.8 HPLC chromatogram of YW4 
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Figure 4.10 ESI Mass Spectrum of MC-MMAE 
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Figure 4.12 ESI Mass Spectrum of YW1 
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Figure 4.13 ESI Mass Spectrum of YW2 
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Figure 4.14 ESI Mass Spectrum of YW3 
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Figure 4.15 ESI Mass Spectrum of YW4 
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Table 4.3 Lytic peptide and hybrid peptides MS and HPLC data 
Peptides Purity MW 
LY1 (8) 73% 2847.46 
HY1 (9) 69% 3705.44 
HY2 (10) 70% 3634.36 
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Figure 4.16 ESI Mass Spectrum of LY1 
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Figure 4.17 ESI Mass Spectrum of HY1 
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Figure 4.18 ESI Mass Spectrum of HY2 
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CHAPTER 5:  IN VITRO CYTOTOXICITY OF PEPTIDE-DRUG 
CONJUGATES AND HYBRID PEPTIDES 
 
5.1. Introduction  
Cell viability and cytotoxicity study have been used for drug biological evaluation, 
screening, and cytotoxicity on the cells in vitro to observe the response on cell growth, 
reproduction, and morphology. Cell cytotoxicity test is an important indicator for 
toxicity evaluation of compound as it is simple, fast, and highly sensitive. Various 
cytotoxicity assays are based on the cell viability at different stages of the cell cycles. 
Lactate dehydrogenase (LDH) assay and trypan blue exclusion assay are membrane 
integrity assay used to evaluate the extent of cell damage by cytotoxicity agents. To 
analyze the cellular metabolic activity, MTT [3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyltetrazolium bromide] assay is a sensitive and reliable indicator as 
compared to ATP and 3H-thymidine incorporation assay, which is used to measure 
the end-point of viable cells. Despite the fact that MTT assay is a sensitive and 
reliable method, drug-efflux pump inhibitor or anti-oxidants may interfere with the 
MTT assay resulting in a false test result. 
  To overcome the drawback of MTT assay, Sulforhodamine B (SRB) assay was 
proposed by Skehan in 1990 and applied to large-scale drug screening by Vichal and 
Kirtikara in 2006 [86][87]. SRB assay determines cell viability by measuring the 
cellular protein content. The death of cells can be observed by staining the cellular 
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DNA with propidium iodide staining method, followed by flow cytometry [88]. SRB 
is a protein dye that binds to protein in a pH-dependent condition of cell protein 
amino acid residues fixed by trichloroacetic acid. SRB binds to protein in mild acidic 
condition, while it can be extracted and solubilized for quantitative measurement 
under basic conditions [86]. Linear relation between the cell number and cellular 
protein measured at cellular densities can reach 1–200‰ of confluence. As compared 
to MTT and other cell cytotoxicity assay, the SRB assay was performed with similar 
results and a stable end-point makes it an appropriate and sensitive assay for 
measuring the cytotoxicity of peptide–drug conjugates. 
The purpose of this chapter is to utilize SRB assay to measure the cytotoxicity of 
synthesized peptide-drug conjugates and hybrid peptides.  
5.2. Materials  
MDA-MB 361, ZR75, and HEK293 cells were purchased from ATCC (Manassas, 
VA, USA). Dulbecco’s modified eagle medium (DMEM), 4.5 g/L glucose, 
L-glutamine and 1% penicillin-streptomycin (5000 I.U./mL) were obtained from 
Mediatech (Manassas, VA, USA). Sodium pyruvate containing 10% heat-inactivated 
fetal bovine serum was ordered from Gemini (Sacramento, CA, USA). 
Trichloroacetic acid, acetic acid, and tris base were obtained from Chem-Impex 
International Inc. (Wood Dale, IL, USA). SRB was obtained from MP Biomedical, 
Inc. (Santa Ana, CA, USA). The 96-well plates were purchased from Santa Cruz 
Biotechnology, Inc.. 
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5.3. Methods 
The cytotoxicity study of MMAE, peptide–drug conjugates, lytic peptides, and 
hybrid peptides was performed using MDA-MB 361, ZR75 cells, and HEK293 cells. 
The cells were cultured in 75-cm2 culture flasks in DMEM medium supplements with 
10% FBS and 1% penicillin-streptomycin. The cells were seeded into 96-well plates 
at a density of 1.25 x 104/mL and grown for 24 h until they were attached to the wells. 
The cells were then incubated with MMAE, peptides, and peptide–drug conjugates at 
the following concentrations: 0.0001, 0.001, 0.01, 0.1, 1, 10, 100, 1000, and 10000 
nM. After 72 hours, the 96-well plates were removed from incubator and 50-µL of 
pre-chilled 50% trichloroacetic acid was added to each well and then the plates were 
stored at 4°C refrigerator for 1 hour to fix the cells. Finally, the cells were washed 
with deionized water 5 times. After drying at the room temperature, the cellular 
proteins were stained by adding 60 µL of 0.4% SRB prepared in 1% acetic acid. After 
20-min staining, the unbound dye was removed by washing with 1% acetic acid for 5 
times. After drying in the air overnight, the cell-bounded SRB was dissolved in 150 
µL of 10 mM non-buffered Tris-base solution at pH 10.5. The SRB absorbance was 
measured at 490 nm wavelength by using a microplate reader (BioTek Instruments, 
Inc., VT, USA).  
The percent of cell viability was calculated by using the following equation:  
Percent of cell cytotoxicity = (At-Ab)/Ab 
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At = Absorbance value of test compound 
Ab = Absorbance value of blank 
Percent of cell viability = 1-(Percent of cell cytotoxicity) 
The percent of cell viability was analyzed using the Graph Pad Prism Version 7 
software (GraphPad Software Inc, CA, USA) with a nonlinear regression 
dose-response curve fit (variable slope three parameter equation). 
5.4. Results and Discussion 
Cytotoxicity studies were performed to determine the potency of peptide, drug, 
and peptide–drug conjugates. As shown in Table 5.1, the tubulin inhibitor MMAE 
demonstrated similar potent cytotoxicity and IC50 in both HER2-positive cell line and 
HER2-negative normal cell line, which indicated the lack of specificity of the drug. 
Peptides showed low toxicity in both HER2-positive cell lines and normal cell line as 
compared with MMAE.  
As for the toxicity of MMAE intermediate, the MC-MMAE exhibited a low 
toxicity similar to that of the peptides. Furthermore, when conjugating MC-MMAE 
with HER2-targeting peptide, the peptide–drug conjugates YW1 and YW2 presented 
an even lower potency than MMAE intermediate in both HER2-positive cell lines and 
normal cell line. There is the minor difference of toxicity of MC-MMAE PDC 
between the HER2-positive cell line and HER2-negative cell line as shown in Table 
5.1. This result indicated that PDCs with MC linker selectively bind to HER2 
overexpressed cell lines due to the lower toxicity in the normal cell line. MC-MMAE 
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PDCs demonstrated lower toxicity in HER2-negative cell line as compared to the 
toxicity in the HER2-positive cell line. This may be attributed to the non-cleavable 
linker maleimidocaproyl, when conjugated with MMAE, the structure of MMAE was 
modified and the toxicity of MMAE was altered. Moreover, the amide bond between 
6-maleimidocaproic acid and MMAE is stable and difficult to be cleaved by a 
protease enzyme.  
In case of a cleavable MMAE intermediate, the MC-VC-MMAE exhibited 
similar high potency as MMAE, when MC-VC-MMAE was conjugated with 
HER2-targeting peptide, the peptide–drug conjugates YW3 and YW4 presented with 
higher potency in the HER2-positive cell lines MDA-MB 361 and ZR75 and a distinct 
lower toxicity in the normal cell line HEK 293 in comparison to MMAE. Both 
peptide-drug conjugates displayed higher toxicity in HER2-positive cell lines 
MDA-MB 361 and ZR 75 as compared to the normal cell line HEK293 as shown in 
Table 5.1. This result indicated that the peptide–drug conjugates based on cleavable 
linker selectively binds to and internalizes via the receptor-mediated endocytosis in 
HER2 overexpressed cell lines.  
The proposed cell-killing mechanism of PDCs based on the MC-VC-PABC 
linker may start upon binding of targeting peptides to HER2, which is overexpressed 
on the surface of the cancer cells. After binding, the PDC-HER2 complex undergoes 
internalization through receptor-mediated endocytosis. Following the internalization, 
the complex releases cytotoxic agents after protease (Cathepsin B) cleavage. Then, 
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after spontaneous elimination of p-aminobenzoyloxycarbonyl (PABC), the cytotoxic 
agent MMAE was released and it exerted its cytotoxic effect by binding to tubulin 
and inhibiting polymerization, leading to apoptosis of the target cells. In comparing to 
the MC-MMAE PDC results, it can conclude that the linker or derivation of MMAE 
to link to targeting peptides play a crucial role in cytotoxicity for HER2 overexpress 
cells. Although the data from MC MMAE PDC would not provide indication of 
specificity of binding and internalization, the MC MMAE PDC could bind and 
internalized into HER 2 overexpress cells.  However, the low potency of MC 
MMAE may not exert its cytotoxicity. The significant low toxicity of both 
MC-MMAE PDCs and VC-MMAE PDCs in HER2 overexpress cells compared to 
normal cells indicated the specificity of PDCs. 
As shown in Table 5.2, the lytic peptide demonstrated similar cytotoxicity and 
IC50 in both HER2-positive cell line and normal cell line, which indicated the lack of 
specificity of the lytic peptides. 10-folds higher toxicity of hybrid peptides than lytic 
peptides was observed on HER2-positive cell line ZR 75 and MDA-MB 361. 
Approximately 5-folds lower toxicity of hybrid peptide than lytic peptides was 
detected on the normal cell line. Furthermore, the significant higher cytotoxicity of 
hybrid peptides on HER2 positive cell line compared to the cytotoxicity on the normal 
cell line exhibited the enhanced specificity of hybrid peptides. By conjugating the 
lytic peptide with HER2-targeting peptide, the hybrid peptides demonstrated 
selectivity on killing HER2 positive cell lines.  
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Table 5.1 In-vitro cytotoxicity of PDCs and free MMAE, MMAE intermediate on 
HER2 positive cell lines and normal cell lines** 
 
Cell line ZR75 MDAMB 361 HEK293 	   IC50 (nM, Avg±SD) 
MMAE* 7.59±0.39 (1.35±0.02)×10-1 6.68±0.15 
MC-MMAE (1.33±0.09)×104 (7.07±0.14)×103 (1.04±0.13)×103 
YW1 (3.95±0.07)×104 (1.46±0.02)×104 (3.29±0.07)×104 
YW2 (7.40±0.91)×104 (3.89±0.04)×104 (3.91±0.04)×104 
VCMMAE 4.43±0.13 (4.16±0.12)×10-1 5.45±0.37 
YW3 (7.00±0.32)×10-3 (3.90±0.16)×10-2 (1.22±0.17)×102 
YW4 (1.30±0.02)×10-2 (1.50±0.05)×10-2 (1.55±0.28)×102 
MARAKE (5.52±0.08)×104 (1.80±0.06)×104 (6.11±0.17)×104 
 Abbreviations: Avg=Average (n=6); SD= Standard deviation 
 * P<0.001 P-values were determined by analysis of variance (ANOVA). 
 ** P<0.0001 P-values were determined by analysis of variance (ANOVA). 
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Table 5.2 In-vitro cytotoxicity of lytic peptide and hybrid peptides on 
HER2-positive cell lines and normal cell lines* 
 
Cell line ZR75 MDAMB361 HEK293 
  IC50 (nM, Avg±SD) 
LY1 83±1.5 301±12 (1.30±0.01)×102 
HY1 6.58±0.61 21.1±1.4 (5.01±0.09)×102 
HY2 2.88±0.27 32.3±0.27 (5.45±0.13)×103 
MARAKE (5.52±0.03)×104 (1.80±0.12)×104 (6.11±0.27)×104 
Abbreviations: Avg=Average (n=6); SD= Standard deviation  
* P<0.001 P-values were determined by analysis of variance (ANOVA). 
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Figure 5.1 IC50 value of MMAE, MC-MMAE, peptide and PDC on MDA-MB 
361 cell line.  
 
 
 
 
Figure 5.2 IC50 value of MMAE, MC-MMAE, peptide and PDC on ZR75 cell 
line.  
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Figure 5.3 IC50 value of MMAE, MC-MMAE, peptide and PDC on HEK293 cell 
line.  
 
 
 
Figure 5.4 IC50 value of MMAE, VC-MMAE, peptide and PDC on MDA-MB 361 
cell line. 
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Figure 5.5 IC50 value of MMAE, VC-MMAE, peptide and PDC on ZR75 cell 
line.  
 
 
 
Figure 5.6 IC50 value of MMAE, VC-MMAE, peptide and PDC on HEK293 cell 
line.  
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Figure 5.7 IC50 value of lytic peptide and hybrid peptides on MDA-MB 361 cell 
line.  
 
 
Figure 5.8 IC50 value of lytic peptide and hybrid peptides on ZR75 cell line.  
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Figure 5.9 IC50 value of lytic peptide and hybrid peptides on HEK293 cell line 
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CHAPTER 6:   SUMMARY AND CONCLUSIONS 
 
In this study, HER2-targeting peptides MARAKE and MARSGL were used as a 
target moiety to design peptide–drug conjugates and hybrid peptides. Both 
non-cleavable and cleavable linkers were used for developing the peptide–drug 
conjugates.  Melittin, a cytolytic peptide was used as a cytotoxic agent to conjugate 
with same HER-targeting peptides to form the hybrid peptides.  
To verify the binding specificity of targeting peptides and their derivative, two 
cell lines that overexpress HER2 and one control cell line without HER2 expression  
were used to prove the specificity of the HER2-targeting peptides. Confocal 
microscopy study was performed to verify the uptake of peptides on these cell lines. 
The result indicated that the peptides and cysteine-modified peptides were bond and 
internalized selectively into the HER2-overexpressed cell lines. The random peptide 
as control showed negligible uptake as compared to HER2-targeting peptides. 
Two designs using peptide-drug conjugate were studied in this thesis. Both 
designs used HER2 binding peptides as targeting moieties, but the drug portion of 
peptide-drug conjugate was either cytolytic peptide or cytotoxic small molecule. 
Peptide–drug conjugates were designed by linking HER2-targeting peptides  
and MMAE, a highly potent and non-specific anti-cancer drug, via MC or VC linker. 
The results showed that the MC linker-based peptide–drug conjugates did not exhibit 
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any toxicity in both HER2-overpressed cell lines and normal cell lines. To the 
cleavable VC linker, the peptide–drug conjugates were 10-folds more cytotoxic to 
HER2-overpressed cancer cells as compared to the drug itself and were 100-fold less 
cytotoxic to cells with no HER2 expression. These results suggest that the use of 
peptide–drug conjugate approach could be a potential approach in cancer therapy. 
Hybrid peptides with cytolytic peptide and HER2-targeting peptide MARAKE 
and MARSGL were also designed by using a GGG as a spacer to link the two 
peptides. The sequence of the designed hybrid peptides was 35 amino acids.  Due to 
the high molecular weight, high purity of hybrid peptides was not obtained. The 
purity of peptides was 70 %. However, the purity of peptide was sufficient for in vitro 
toxicity study. The preliminary cytotoxicity study demonstrated limited potential of 
hybrid peptides. Both hybrid peptides showed slightly enhanced toxicity in the 
HER2-overpressed cell lines as compared to the lytic peptide while reducing toxicity 
to non-HER2 overexpress cells. These results may lead to the further studies in 
designing hybrid peptides with shorter and more potent lytic peptides. 
In conclusion, HER2-targeted delivery peptide–drug conjugates were 
successfully synthesized by using an enzyme-sensitive cleavable linker. Peptide–drug 
conjugates using non-cleavable linker did not enhance the toxicity to the cancer cell 
lines. Hybrid peptide is a potential approach for cancer therapy but further research 
with different lytic peptides will be needed. 
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